Skip directly to content

July 17, 2018 – Treatment Action Group (TAG) submitted comments to the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) in response to a public request for information (RFI) to inform NIAID's Tuberculosis Strategic Plan on supporting TB research and development (R&D).

View or download the comment. 

This comment calls on NIAID to build on its leadership as the single largest funder of TB R&D to further deepen its commitment to catalyze the research necessary to upend the global and domestic TB epidemic.

July 16, 2018 – Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association) join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Our comments call on Congress and the White House to boldly address a broken drug pricing system and to hold the pharmaceutical industry accountable for its role in ensuring that critical disease-preventing and

August 1, 2018
10 am EDT / 4 pm South Africa / 5 pm Kenya


We invite you to join a critical discussion on August 1, 2018 at 10 am New York / 4pm South Africa / 5pm Kenya as TAG, TB CAB, and DR-TB STAT host a webinar on Implementing a bedaquiline-based, injectable-free regimen for drug-resistant tuberculosis.

Dr. Nobert Ndejka from the National Department of Health in South Africa will be talking about the South African experience as the first country to roll out this unique and less toxic regimen. Dr. Maureen Kamene

TAG_2017_ar_cove_250x347.pngAs you’ll see in our latest Annual Report, in 2017 TAG succeeded in fending off attacks on the ACA and savage budget cuts to NIH, CDC, the President’s Emergency Plan for AIDS Relief (PEPFAR), and the AIDS Drug Assistance Programs (ADAPs). These and other threats to our health, rights, and lives will continue as long as the current Administration and Congress are in office.

As two of TAG’s newest board members, we’re pleased to make a very special announcement: thanks to a generous longtime TAG supporter, all donations made in response to this message by July 31, 2018 will be matched up to

The following letter from TAG Executive Director, Mark Harrington, and Dr. Demetre Daskalakis, Deputy Commissioner of Disease Control at the New York City Department of Health and Mental Hygiene, to The New York Times was published on July 5, 2018.

Preventing HIV
July 5, 2018

To the Editor:

Re “The End of Safe Gay Sex?,” by Patrick William Kelly (Opinion Piece,, June 26):

Condoms work when used consistently.


TB Research Briefing for UN Missions:

This briefing in New York City on June 4, 2018 provided an opportunity for discussion on the importance of investing in the full spectrum of TB research, and adopting principles to guide research to ensure efficiency and equitable access. The event featured Dr. Soumya Swaminathan, Deputy Director General for Programmes, World Health Organization, as the keynote speaker and then had three panels.

The full event can be seen here.

Watch the Introduction and Keynote Remarks.

  • Introduction: Mark Harrington,

Forging a Path to HCV Elimination: Simpler Tests and Affordable Generics
Report of the World Community Advisory Board on HCV Generics and Diagnostics
July 18–20 2017, Bangkok, Thailand

Community Advisory Boards have long played an important role in the push to expand access to medicines and in the formulation of demands for improved responses to public health challenges. HCV Community Advisory Boards have borrowed from the precedent established by HIV activists.

Countries and donors must do more to ensure all people with TB have access; further price reductions for newer medicines required

NEW YORK, NY – June 19, 2018 Treatment Action Group (TAG) welcomes the announcement  from the Stop TB Partnership’s Global Drug Facility (GDF) that new agreements have substantially lowered the price of medicines used to treat tuberculosis (TB).1 The GDF estimates that USD 31 million will be saved as a result.

These dramatic cost savings must be put into diagnosing and treating more patients, as the World Health Organization (WHO) estimates that only 26% of

Ending the Epidemic: Building Effective Collaboration between Community Advocates and Health Departments, presented by Treatment Action Group and Housing Works, May 31, 2018

Since 2014, community-led Ending the Epidemic (EtE) initiatives have advanced across the nation, setting ambitious targets to reduce HIV incidence below epidemic levels in states, counties, and cities in the US. Aligning the priorities of state and city health departments with the priorities of the communities they serve is an essential part of the EtE process.